Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00664482 · ClinicalTrials.gov registry record · NA
A Single-Patient Study Using AGS 006
A NA study, sponsored by Argos Therapeutics.
- Completed
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT00664482: Completed NA study, sponsored by Argos Therapeutics.
NCT00664482 is a NA study that has completed, run by Argos Therapeutics. The registered enrollment target is 1 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00664482, a NA study, has completed, sponsored by Argos Therapeutics.
- COMPLETED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
Argos Therapeutics, Inc., (Argos) proposes to study AGS-006 in a subject with newly diagnosed resectable pancreatic cancer. The AGS 006 immunotherapeutic may potentially offer a desired additional option to conventional treatments for pancreatic carcinoma.
Interventions
- BIOLOGICAL AGS-006
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2007-05 |
| Est. Completion | 2011-10 |
| Phase | NA |
What the finished NCT00664482 record still lists
NCT00664482 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which AGS-006 is the first listed.
NCT00664482 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00664482 about?
NCT00664482 is a clinical study titled "A Single-Patient Study Using AGS 006". Argos Therapeutics, Inc., (Argos) proposes to study AGS-006 in a subject with newly diagnosed resectable pancreatic cancer. The AGS 006 immunotherapeutic may potentially offer a desired additional option to conventional treatments for pancreatic carcinoma.
What is the current status of trial NCT00664482?
This trial is currently completed. It is a NA study. The enrollment target is 1 participants. The study started on 2007-05. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00664482?
The interventions under investigation include: AGS-006 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00664482?
This trial is sponsored by Argos Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00664482's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia